Welcome to our dedicated page for Immunome news (Ticker: IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.
Immunome Inc (IMNM) is a clinical-stage biopharmaceutical company advancing novel antibody therapies for cancer and infectious diseases through its proprietary human memory B cell platform. This page serves as the definitive source for verified corporate announcements, research milestones, and financial disclosures.
Investors and industry professionals will find timely updates on clinical trial progress, strategic collaborations like the Nectin Therapeutics partnership, and regulatory developments. Our curated news collection enables efficient tracking of Immunome's expanding oncology pipeline and infectious disease programs.
Key content categories include therapy development updates, intellectual property announcements, executive leadership changes, and quarterly financial results. All materials are sourced from official company communications and vetted industry reports.
Bookmark this page for streamlined access to Immunome's latest scientific advancements and business developments. For comprehensive analysis of IMNM stock performance, visit Stock Titan's dedicated market data section.
Immunome (Nasdaq: IMNM) has completed the acquisition of antibodies and related assets from Atreca for $5.5 million upfront and up to $7 million in clinical development milestones. The purchase includes rights to 28 antibodies and various materials, enhancing Immunome's ADC (antibody-drug conjugates) portfolio. Immunome's Chief Scientific Officer, Jack Higgins, emphasizes that the newly acquired antibodies align with their strategy targeting novel and unexplored cancer therapy targets. CEO Clay Siegall mentioned that this acquisition aims to expand Immunome's ADC portfolio cost-effectively and accelerate the development of innovative cancer treatments.
Immunome (Nasdaq: IMNM) has announced the promotion of Max Rosett to Chief Financial Officer, effective May 9. Rosett, previously Executive Vice President of Operations and Interim CFO since January 2024, has played a key role in Immunome's recent strategic moves including the merger with Morphimmune and financial transactions worth over $350 million. CEO Clay Siegall emphasized Rosett's strategic insight and financial expertise as vital for advancing the company's pipeline, including the Phase 3 RINGSIDE trial of AL102 and preparing IM-1021 and IM-3050 for IND submission. Rosett's background includes senior roles at Morphimmune and experience at Research Bridge Partners, Google, and Boston Consulting Group.
Immunome (Nasdaq: IMNM), a biotech company focused on targeted cancer therapies, reported its Q1 2024 financial results and provided a business update. The company has integrated AL102 and IM-1021 and is progressing towards regulatory submissions. Topline data for the Phase 3 RINGSIDE trial of AL102 is expected in H2 2025. IND submissions for IM-1021 and IM-3050 are anticipated in Q1 2025. Financially, Immunome has $309.7 million in cash and equivalents, with a runway extending into 2026. Q1 2024 expenses included $15.4 million in R&D, $112 million in in-process R&D from recent acquisitions, and $6 million in administrative costs. The company posted a net loss of $129.5 million, or $2.51 per share.
Immunome, Inc. (IMNM) will be presenting at the 2024 Bank of America Healthcare Conference. The President and CEO, Clay Siegall, will present on May 15, 2024. Interested parties can access the live webcast on the company's website.
Immunome, Inc. (Nasdaq: IMNM) has appointed Kinney Horn as Chief Business Officer, bringing extensive experience in life sciences corporate and business development to the company. With the recent acquisition of AL102, Immunome is now a clinical stage company, aiming to enhance its development capabilities and expand its portfolio of targeted cancer therapies. Mr. Horn's successful track record in strategic partnerships will play a important role in Immunome's growth.
FAQ
What is the current stock price of Immunome (IMNM)?
What is the market cap of Immunome (IMNM)?
